Binding of prostate-specific membrane antigen to dendritic cells: A critical step in vaccine preparation

Stefano Garetto, Federico Sizzano, Davide Brusa, Alessandro Tizzani, Fabio Malavasi, Lina Matera

Research output: Contribution to journalArticle

Abstract

Background aims Dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer (PCa), and prostate-specific membrane antigen (PSMA) fulfils the requirements for a tumor-associated antigen (TAA) to be clinically effective. We evaluated the actual binding of selected HLA-A2-restricted PSMA peptides to HLA class I molecules on ex vivo-generated mature (m) DC. Methods mDC were generated from peripheral monocytes of HLA-A2 normal donors. The PSMA peptides PSMA711 (ALFDIESKV), PSMA27 (VLAGGFFLL) and PSMA663 (MMNDQLMFL) were selected based on computer-assisted prediction programs, documented CTL epitope activity or previous use in clinical trials. The model cell line T2 and the clinical grade (CD831 CCR71) mDC were pulsed with fluorescein (FL)-conjugated peptides and an anti-HLA-A2 monoclonal antibody (MAb) and analyzed. Results Flow cytometry analysis showed best binding efficiency to be by PSMA27. Confocal microscopy confirmed coincident fluorescence emission of HLA-A2 MAb and FLPSMA27. Virtual co-localization of PSMA27 and HLA class I molecules was supported further by fluorescence resonance energy transfer (FRET) analysis. The clinical relevance of our findings has to be validated in vivo. Conclusions The present report is the first to score selected PSMA peptides based on their detectable binding to mDC. It identifies PSMA27 as the choice candidate among other PSMA peptides and it should be included in developing DC vaccine protocols for HLA-A2 PCa patients.

Original languageEnglish
Pages (from-to)1090-1100
Number of pages11
JournalCytotherapy
Volume11
Issue number8
DOIs
Publication statusPublished - 2009

Fingerprint

HLA-A2 Antigen
Dendritic Cells
Vaccines
Peptides
Prostatic Neoplasms
Monoclonal Antibodies
Fluorescence Resonance Energy Transfer
Neoplasm Antigens
Fluorescein
Confocal Microscopy
Epitopes
Monocytes
Flow Cytometry
Fluorescence
human glutamate carboxypeptidase II
Tissue Donors
Clinical Trials
Cell Line

Keywords

  • Antigenic peptides
  • Dendritic cells
  • Prostate cancer
  • Prostate-specifi c membrane antigen
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Garetto, S., Sizzano, F., Brusa, D., Tizzani, A., Malavasi, F., & Matera, L. (2009). Binding of prostate-specific membrane antigen to dendritic cells: A critical step in vaccine preparation. Cytotherapy, 11(8), 1090-1100. https://doi.org/10.3109/14653240903164971

Binding of prostate-specific membrane antigen to dendritic cells : A critical step in vaccine preparation. / Garetto, Stefano; Sizzano, Federico; Brusa, Davide; Tizzani, Alessandro; Malavasi, Fabio; Matera, Lina.

In: Cytotherapy, Vol. 11, No. 8, 2009, p. 1090-1100.

Research output: Contribution to journalArticle

Garetto, S, Sizzano, F, Brusa, D, Tizzani, A, Malavasi, F & Matera, L 2009, 'Binding of prostate-specific membrane antigen to dendritic cells: A critical step in vaccine preparation', Cytotherapy, vol. 11, no. 8, pp. 1090-1100. https://doi.org/10.3109/14653240903164971
Garetto, Stefano ; Sizzano, Federico ; Brusa, Davide ; Tizzani, Alessandro ; Malavasi, Fabio ; Matera, Lina. / Binding of prostate-specific membrane antigen to dendritic cells : A critical step in vaccine preparation. In: Cytotherapy. 2009 ; Vol. 11, No. 8. pp. 1090-1100.
@article{437b8788a60b43b593780dcd9bbf6733,
title = "Binding of prostate-specific membrane antigen to dendritic cells: A critical step in vaccine preparation",
abstract = "Background aims Dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer (PCa), and prostate-specific membrane antigen (PSMA) fulfils the requirements for a tumor-associated antigen (TAA) to be clinically effective. We evaluated the actual binding of selected HLA-A2-restricted PSMA peptides to HLA class I molecules on ex vivo-generated mature (m) DC. Methods mDC were generated from peripheral monocytes of HLA-A2 normal donors. The PSMA peptides PSMA711 (ALFDIESKV), PSMA27 (VLAGGFFLL) and PSMA663 (MMNDQLMFL) were selected based on computer-assisted prediction programs, documented CTL epitope activity or previous use in clinical trials. The model cell line T2 and the clinical grade (CD831 CCR71) mDC were pulsed with fluorescein (FL)-conjugated peptides and an anti-HLA-A2 monoclonal antibody (MAb) and analyzed. Results Flow cytometry analysis showed best binding efficiency to be by PSMA27. Confocal microscopy confirmed coincident fluorescence emission of HLA-A2 MAb and FLPSMA27. Virtual co-localization of PSMA27 and HLA class I molecules was supported further by fluorescence resonance energy transfer (FRET) analysis. The clinical relevance of our findings has to be validated in vivo. Conclusions The present report is the first to score selected PSMA peptides based on their detectable binding to mDC. It identifies PSMA27 as the choice candidate among other PSMA peptides and it should be included in developing DC vaccine protocols for HLA-A2 PCa patients.",
keywords = "Antigenic peptides, Dendritic cells, Prostate cancer, Prostate-specifi c membrane antigen, Vaccines",
author = "Stefano Garetto and Federico Sizzano and Davide Brusa and Alessandro Tizzani and Fabio Malavasi and Lina Matera",
year = "2009",
doi = "10.3109/14653240903164971",
language = "English",
volume = "11",
pages = "1090--1100",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Binding of prostate-specific membrane antigen to dendritic cells

T2 - A critical step in vaccine preparation

AU - Garetto, Stefano

AU - Sizzano, Federico

AU - Brusa, Davide

AU - Tizzani, Alessandro

AU - Malavasi, Fabio

AU - Matera, Lina

PY - 2009

Y1 - 2009

N2 - Background aims Dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer (PCa), and prostate-specific membrane antigen (PSMA) fulfils the requirements for a tumor-associated antigen (TAA) to be clinically effective. We evaluated the actual binding of selected HLA-A2-restricted PSMA peptides to HLA class I molecules on ex vivo-generated mature (m) DC. Methods mDC were generated from peripheral monocytes of HLA-A2 normal donors. The PSMA peptides PSMA711 (ALFDIESKV), PSMA27 (VLAGGFFLL) and PSMA663 (MMNDQLMFL) were selected based on computer-assisted prediction programs, documented CTL epitope activity or previous use in clinical trials. The model cell line T2 and the clinical grade (CD831 CCR71) mDC were pulsed with fluorescein (FL)-conjugated peptides and an anti-HLA-A2 monoclonal antibody (MAb) and analyzed. Results Flow cytometry analysis showed best binding efficiency to be by PSMA27. Confocal microscopy confirmed coincident fluorescence emission of HLA-A2 MAb and FLPSMA27. Virtual co-localization of PSMA27 and HLA class I molecules was supported further by fluorescence resonance energy transfer (FRET) analysis. The clinical relevance of our findings has to be validated in vivo. Conclusions The present report is the first to score selected PSMA peptides based on their detectable binding to mDC. It identifies PSMA27 as the choice candidate among other PSMA peptides and it should be included in developing DC vaccine protocols for HLA-A2 PCa patients.

AB - Background aims Dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer (PCa), and prostate-specific membrane antigen (PSMA) fulfils the requirements for a tumor-associated antigen (TAA) to be clinically effective. We evaluated the actual binding of selected HLA-A2-restricted PSMA peptides to HLA class I molecules on ex vivo-generated mature (m) DC. Methods mDC were generated from peripheral monocytes of HLA-A2 normal donors. The PSMA peptides PSMA711 (ALFDIESKV), PSMA27 (VLAGGFFLL) and PSMA663 (MMNDQLMFL) were selected based on computer-assisted prediction programs, documented CTL epitope activity or previous use in clinical trials. The model cell line T2 and the clinical grade (CD831 CCR71) mDC were pulsed with fluorescein (FL)-conjugated peptides and an anti-HLA-A2 monoclonal antibody (MAb) and analyzed. Results Flow cytometry analysis showed best binding efficiency to be by PSMA27. Confocal microscopy confirmed coincident fluorescence emission of HLA-A2 MAb and FLPSMA27. Virtual co-localization of PSMA27 and HLA class I molecules was supported further by fluorescence resonance energy transfer (FRET) analysis. The clinical relevance of our findings has to be validated in vivo. Conclusions The present report is the first to score selected PSMA peptides based on their detectable binding to mDC. It identifies PSMA27 as the choice candidate among other PSMA peptides and it should be included in developing DC vaccine protocols for HLA-A2 PCa patients.

KW - Antigenic peptides

KW - Dendritic cells

KW - Prostate cancer

KW - Prostate-specifi c membrane antigen

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=71149112331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71149112331&partnerID=8YFLogxK

U2 - 10.3109/14653240903164971

DO - 10.3109/14653240903164971

M3 - Article

C2 - 19929472

AN - SCOPUS:71149112331

VL - 11

SP - 1090

EP - 1100

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 8

ER -